Experience

Medicines Discovery Catapult

• United Kingdom
• Biotechnology
• 100 - 200 Employee

• Lead Scientist

  • May 2023 - Present

• Senior Scientist

  • Sep 2020 - May 2023



The University of Manchester

• United Kingdom
• Higher Education
• 700 & Above Employee

• Preclinical Research Scientist

  • Apr 2018 - Apr 2020

  Research area: Nanotechnology, Neuro-oncology, Drug delivery The principle objective was to exploit the unique properties of graphene-based materials to develop innovative solutions for unmet clinical need (EPSRC funded). My specific role was to establish and optimise preclinical cancer models for evaluating the potential of graphene-based materials as multifunctional drug delivery platforms. Furthermore, to apply existing imaging modalities (MRI, optical) to determine in vivo functionality and therapeutic efficacy of novel graphene-based nanocarriers. Show less



The University of Sheffield

• Higher Education
• 700 & Above Employee

• Senior Research Associate

  • Apr 2014 - Apr 2018

  Research area: Alzheimer's disease, cerebral blood flow, neuroimaging.The principle objective was to explore the pathogenic contribution of cerebrovascular dysfunction in Alzheimer's disease (ARUK funded). My role was to provide scientific expertise at all stages of the research programme including the design, execution, data interpretation and communication. This involved implementing novel in vivo imaging research methodologies, performance management to meet project milestones, direct supervision of researchers, develop the team's strategic interests through internal/external collaborations and disseminate the research findings through high-quality publications and conference presentations. Show less

• Project Manager

  • Jul 2009 - Oct 2014

  Research area: Nanotechnology, Pharmaceutics, Neurodegenerative disease.The principle objective was to demonstrate proof-of-principle for a polymer-based nanoparticle drug delivery system targeting the CNS (EPSRC funded). My role was to manage the development pipeline of new polymer formulations from optimising in vitro functional assays, through to applying in vivo optical methods to evaluate nanoparticle pharmacokinetics/biodistribution and developing high-resolution microscopy to determine penetrance into the CNS. Efficient and effective communication across cross-functional groups to support the flow of information was paramount in order to achieve project ambitions. Show less



Imperial College London

• Research Services
• 700 & Above Employee

• Postdoctoral Research Associate

  • Jun 2004 - Jul 2009

  Research area: Neuromuscular medicine The overarching theme was to develop viral and non-viral genetic therapies to treat motor neurone disease and Duchenne muscular dystrophy (Dept. of Health UK funded). My primary responsibilities were to manage, collate, interpret and communicate high quality translational data to accelerate the development of novel therapeutic strategies for neuromuscular diseases. My key outputs were focused on the preclinical functional evaluation of gene-modifying approaches, achieved either though the generation of transgenic overexpressing mice, viral gene therapy, or exon-skipping based strategies. A significant development has been the first FDA-approved Duchenne muscular dystrophy treatment (EXONDYS 51), an exon skipping therapy that in principle is the same strategy that showed much promise in preclinical evaluations that I conducted (see links). Show less



University of Alberta

• Canada
• Higher Education
• 700 & Above Employee

• Postdoctoral Fellow

  • May 2003 - Jun 2004

  Research area: Neurodegenerative disease The principle objective was to advance our understanding of the pathophysiology of motor neurone disease (CIHR funded). My role was to implement a rejsearch program to characterise disease progression in a mouse model of MND and investigate whether promoting peripheral nerve regeneration can ameliorate disease severity. Research area: Neurodegenerative disease The principle objective was to advance our understanding of the pathophysiology of motor neurone disease (CIHR funded). My role was to implement a rejsearch program to characterise disease progression in a mouse model of MND and investigate whether promoting peripheral nerve regeneration can ameliorate disease severity.